Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › DNTH

SILVERARC CAPITAL MANAGEMENT, LLC position in DNTH

DIANTHUS THERAPEUTICS INC · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 236,582 shares of DNTH (DIANTHUS THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$20.8M, representing 2.66% of its reported portfolio and ranking #11 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed DNTH holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

Latest position (Q3 2026)236.58K sh
Reported value held$20.83M
Portfolio Weight2.66%
First reportedQ1 2025
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's DNTH position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in DNTH in Q1 2025 at 190,334 shares (US$3.5M). The position peaked in Q1 2026 at 654,746 shares, worth US$54.9M. Across 7 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 236,582 shares valued at US$20.8M — a reduction of -153,418 shares quarter over quarter.. Notable position changes include a 50% trim in Q2 2025 (shares rose 111% over the following quarter), a 605% increase in Q3 2025 (shares rose 5% over the following quarter), a 40% trim in Q2 2026 (shares fell 10% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 190.33K $3.45M New
Q2 2025 95.81K $1.78M Reduce
Q3 2025 674.97K $26.56M Add
Q4 2025 750.14K $30.91M Add
Q1 2026 654.75K $54.95M Reduce
Q2 2026 390.00K $38.02M Reduce
Q3 2026 236.58K $20.83M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DNTH and 13F data

DNTH (DIANTHUS THERAPEUTICS INC) is a Health Care company. 62 other funds we track also report a position in DNTH — the largest reported positions include Fairmount Funds Management LLC (US$247.3M), Avidity Partners Management LP (US$205.1M), Octagon Capital Advisors LP (US$179.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DNTH

All DNTH fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held DNTH?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed DNTH holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in DNTH?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 236.58K shares of DNTH (DIANTHUS THERAPEUTICS INC), valued at $20.83M, representing 2.66% of its reported portfolio and ranking #11.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling DNTH?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in DNTH. The position peaked in Q1 2026 at 654.75K shares.

Which other funds hold DNTH?

Other major institutional holders of DNTH include Fairmount Funds Management LLC, Avidity Partners Management LP, Octagon Capital Advisors LP, among 62 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.